Terms: = Breast cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Treatment
28225 results:
1. Patient experiences and needs in cancer care- results from a nationwide cross-sectional study in Germany.
Ziegler E; Klein J; Kofahl C
BMC Health Serv Res; 2024 May; 24(1):572. PubMed ID: 38698426
[TBL] [Abstract] [Full Text] [Related]
2. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
3. Targeted photodynamic therapy technique of Janus nanoparticles on breast cancer.
Montaseri H; Abrahamse H
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):270-277. PubMed ID: 38696132
[TBL] [Abstract] [Full Text] [Related]
4. A novel preclinical model of the normal human breast.
Wilby AJ; Cabral S; Zoghi N; Howell SJ; Farnie G; Harrison H
J Mammary Gland Biol Neoplasia; 2024 May; 29(1):9. PubMed ID: 38695983
[TBL] [Abstract] [Full Text] [Related]
5. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With breast cancer.
Shaw JA; Page K; Wren E; de Bruin EC; Kalashnikova E; Hastings R; McEwen R; Zhang E; Wadsley M; Acheampong E; Renner D; Gleason KLT; Ambasager B; Stetson D; Fernandez-Garcia D; Guttery D; Allsopp RC; Rodriguez A; Zimmermann B; Sethi H; Aleshin A; Liu MC; Richards C; Stebbing J; Ali S; Rehman F; Cleator S; Kenny L; Ahmed S; Armstrong AC; Coombes RC
JCO Precis Oncol; 2024 Apr; 8():e2300456. PubMed ID: 38691816
[TBL] [Abstract] [Full Text] [Related]
6. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
7. A Comparative Analysis of Implant-sparing Plan
Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
[TBL] [Abstract] [Full Text] [Related]
8. Neoadjuvant Chemotherapy in Patients with HER2-Negative breast cancer: A Report from Clinical breast cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract] [Full Text] [Related]
9. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
10. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
11. In Vitro Antiviral and Anticancer Effects of Tanacetum sinaicum Essential Oil on Human Cervical and breast cancer.
Sheashea AA; Ahmed FA; El Zayat E; Ebeed BW; Elberry MH; Hassan ZKM; Hafez MM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1457-1471. PubMed ID: 38680008
[TBL] [Abstract] [Full Text] [Related]
12. Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for breast cancer treatment through Computer-Aided Drug Design and In Vitro Analysis.
Fonseca-Benítez V; Acosta-Guzmán P; Sánchez JE; Alarcón Z; Jiménez RA; Guevara-Pulido J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675620
[TBL] [Abstract] [Full Text] [Related]
13. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
[TBL] [Abstract] [Full Text] [Related]
14. Real-World treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract] [Full Text] [Related]
16. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract] [Full Text] [Related]
17. Are depression and poor sleep quality a major problem in Turkish Women receiving chemotherapy for breast cancer?
Buyuksimsek M; Gulmez A; Pirinci O; Tohumcuoglu M; Kidi MM
Rev Assoc Med Bras (1992); 2024; 70(3):e20231377. PubMed ID: 38656011
[TBL] [Abstract] [Full Text] [Related]
18. [Perceived work self-efficacy, and characteristics of return to work in women survivors of breast cancer at two reference centers in Colombia].
Vasquez Trespalacios EM; Oliveros-Riveros LM; Mercado González DC
Arch Prev Riesgos Labor; 2024 Apr; 27(2):140-156. PubMed ID: 38655594
[TBL] [Abstract] [Full Text] [Related]
19. Implementation of a Mindful Walking Intervention in breast cancer Patients After Their Primary Oncologic treatment: Results of a Qualitative Study Within a Randomized Controlled Trial.
Ortiz M; Schröder ML; Brinkhaus B; Stöckigt B
Integr Cancer Ther; 2024; 23():15347354241237972. PubMed ID: 38654515
[TBL] [Abstract] [Full Text] [Related]
20. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract] [Full Text] [Related]
[Next]
